Author/Authors :
Graham H. Timms، نويسنده , , John R. Boot، نويسنده , , Richard J. Broadmore، نويسنده , , Steven L. Carney، نويسنده , , Jane Cooper، نويسنده , , Jeremy D. Findlay، نويسنده , , Jeremy Gilmore، نويسنده , , Stephen Mitchell، نويسنده , , Nick A. Moore، نويسنده , , Ian Pullar، نويسنده , , Graham J. Sanger، نويسنده , , Rosemary Tomlinson، نويسنده , , Beverly B. Tree، نويسنده , , Susan Wedley، نويسنده ,
Abstract :
Incorporation of an SRI (serotonin reuptake inhibitor) pharmacophore into a selective 5-HT1D agonist has led to the discovery of a molecule having both 5-HT1D antagonist and SRI activity. RPS methodology was used to develop the SAR and identify potential approaches to reduce unwanted adrenergic α1 and dopamine D2 cross-reactivities.
Keywords :
5-HT1D antagonist , Serotonin reuptake inhibitor , Rapid parallel synthesis.* Corresponding author. Tel.: +44-1276-483470 , fax: +44-1276-483525 , e-mail: timms_graham_h@lilly.com
